Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
- Resource Type
- journal article
- Authors
- Vogl, Ursula M.; Andalibi, Haleh; Klaus, Alexander; Vormittag, Laurenz; Schima, Wolfgang; Heinrich, Bettina; Kafka, Alice; Winkler, Thomas; Öhler, Leopold
- Source
- BMC Cancer. 1/8/2019, Vol. 19 Issue 1, p1-8. 8p. 3 Charts, 2 Graphs.
- Subject
- *PANCREAS
*ADENOCARCINOMA
*PROGRESSION-free survival
*COMBINATION drug therapy
*FLUOROURACIL
*FOLINIC acid
*ORGANOMETALLIC compounds
*PACLITAXEL
*PANCREATIC tumors
*ALBUMINS
*TREATMENT effectiveness
*RETROSPECTIVE studies
*DEOXYCYTIDINE
- Language
- ISSN
- 1471-2407
Background: Locally advanced or metastatic adenocarcinoma of the pancreas remains - despite the implementation of new chemotherapy protocols - a disease with short overall survival (OS).Methods: Eighty-three patients were treated with locally advanced or metastatic adenocarcinoma of the pancreas with either FOLFIRINOX or nab-Paclitxel and Gemcitabine (nabPGem) as first- or second line therapy. We analysed the outcome for OS and progression-free survival (PFS) in terms of treatment regimen and sequence.Results: The majority of patients presented in good performance status (PS) with a median age of 68 years. Fourty-two patients received FOLFIRINOX as first-line therapy, 41 patients were treated with nabPGem as first line therapy. Forty-eight patients received both treatments. The OS of all 83 patients was 12.6 months (95% CI: 10.7-14.6), resulting in a 1-year OS of 54%. Forty-eight patients received FOLFIRINOX followed by nabPGem or vice versa. There was no significant difference in OS or PFS for either of the two sequences (p = 0.9). The OS for FOLFIRINOX followed by nabPGem or nabPGem followed by FOLFIRINOX was 13.7 months (95% CI: 12.6-14.7) and 13.8 months (95% CI: 8.6-19), respectively.Conclusions: The sequence FOLFIRINOX followed by nab-Paclitaxel and Gemcitabine or vice versa lead to an equal OS outcome. [ABSTRACT FROM AUTHOR]